Join Now

Category Archives: BioUtah News

bioMérieux Recognized as Top 1% by S&P Global

By Natalie Themm | Published March 27, 2025

bioMérieux Recognized as Top 1% by S&P Global

| Tagged | Comments Off on bioMérieux Recognized as Top 1% by S&P Global

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

By Natalie Themm | Published March 27, 2025

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

| Tagged | Comments Off on Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO

By admin | Published March 20, 2025

Marcy l’Étoile, France, March 18th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat […]

| Comments Off on bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO

E&I Ski Day 2025 Recap

By Natalie Themm | Published March 20, 2025

E&I Ski Day 2025 Recap

| Comments Off on E&I Ski Day 2025 Recap

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

By Natalie Themm | Published March 20, 2025

Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

| Tagged | Comments Off on Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

By admin | Published March 13, 2025

Fully Sponsored BioLabs Lab Space to Support Halia’s Next Phase of Development LEHI, Utah, Feb. 25, 2025 /PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for chronic inflammation and obesity-related diseases, announced today that it has been awarded the Novo Nordisk Golden Ticket. This prestigious award provides Halia with a fully sponsored […]

| Comments Off on Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

By Natalie Themm | Published March 13, 2025

The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

| Comments Off on The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants

First Patient Enrolled in Merit Medical’s PREEMIE Study

By Natalie Themm | Published March 13, 2025

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants

| Tagged | Comments Off on First Patient Enrolled in Merit Medical’s PREEMIE Study

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

By Natalie Themm | Published March 13, 2025

iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

| Tagged | Comments Off on iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia

Altitude Lab Demo Day

By Natalie Themm | Published February 20, 2025

As part of BioHive week, Altitude Lab hosted its annual Demo Day.

| Tagged | Comments Off on Altitude Lab Demo Day

Steve Pacelli Appointed CEO of Epitel, Inc.

By Natalie Themm | Published February 13, 2025

Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth

| Tagged | Comments Off on Steve Pacelli Appointed CEO of Epitel, Inc.

Sera Prognostics Announces Pricing of $50 Million Public Offering

By Natalie Themm | Published February 13, 2025

Sera Prognostics Announces Pricing of $50 Million Public Offering

| Tagged | Comments Off on Sera Prognostics Announces Pricing of $50 Million Public Offering

A Special Thanks To Our Legacy and Platinum Elite Members